246 related articles for article (PubMed ID: 32366395)
1. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
[TBL] [Abstract][Full Text] [Related]
2. Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Yamamoto J; Murata T; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Shimoya K; Nomura T; Kurebayashi J; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
Anticancer Res; 2020 May; 40(5):2475-2479. PubMed ID: 32366391
[TBL] [Abstract][Full Text] [Related]
3. A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.
Nomura T; Kurebayashi J; Moriya T; Saito W; Murata T; Yamamoto J; Hozumi C; Hoffman RM
Anticancer Res; 2021 Dec; 41(12):6191-6197. PubMed ID: 34848473
[TBL] [Abstract][Full Text] [Related]
4. A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.
Lim HI; Yamamoto J; Inubushi S; Nishino H; Tashiro Y; Sugisawa N; Han Q; Sun YU; Choi HJ; Nam SJ; Kim MB; Lee JS; Hozumi C; Bouvet M; Singh SR; Hoffman RM
Anticancer Res; 2020 May; 40(5):2481-2485. PubMed ID: 32366392
[TBL] [Abstract][Full Text] [Related]
5. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
6.
Hamada K; Aoki Y; Yamamoto J; Hozumi C; Zhao M; Murata T; Sugisawa N; Bouvet M; Tsunoda T; Hoffman RM
In Vivo; 2021; 35(6):3067-3071. PubMed ID: 34697138
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.
Lim HI; Sun YU; Han Q; Yamamoto J; Hoffman RM
In Vivo; 2021; 35(5):2531-2534. PubMed ID: 34410939
[TBL] [Abstract][Full Text] [Related]
8. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
[TBL] [Abstract][Full Text] [Related]
9. Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Higuchi T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(4):351-358. PubMed ID: 32576580
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
Yonemori K; Shimomura A; Yasojima H; Masuda N; Aogi K; Takahashi M; Naito Y; Shimizu S; Nakamura R; Hashimoto J; Yamamoto H; Hirakawa A; Michimae H; Hamada A; Yoshida T; Sukigara T; Tamura K; Fujiwara Y
Eur J Cancer; 2019 Mar; 109():84-91. PubMed ID: 30703739
[TBL] [Abstract][Full Text] [Related]
12. High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Sep; 118(9):2739-2743. PubMed ID: 28176365
[TBL] [Abstract][Full Text] [Related]
13. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
[TBL] [Abstract][Full Text] [Related]
17. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA
Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285
[TBL] [Abstract][Full Text] [Related]
19. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Kawaguchi K; Kiyuna T; Miyake M; Igarashi K; Zhang Z; Murakami T; Li Y; Nelson SD; Elliott I; Russell T; Singh A; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(6):722-727. PubMed ID: 29334307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
